about
Cardiac toxicity of trastuzumab in elderly patients with breast cancerRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsMyostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment.Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols.Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency.The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity.Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness.Clinical characteristics and prognostic impact of atrial fibrillation in patients with chronic heart failure.Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease.Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs.Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly.Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure.Doxorubicin effect on myocardial metabolism as a pre-requisite for subsequent development of cardiac toxicity: a translational (18)F-FDG PET/CT observation.Comparison of coronary flow reserve estimated by dynamic radionuclide SPECT and multi-detector x-ray CT.Diagnostic value of ischemia severity at myocardial perfusion imaging in elderly persons with suspected coronary disease.Lower limb ischemia due to long-term abuse of cocaine.Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells.5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.Methods, accuracy and clinical implications of atrial fibrillation detection by cardiac implantable electronic devices.Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia.Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.Beyond cardiomyocyte loss: Role of Notch in cardiac aging.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracyclineLinking Heart Failure to CancerThrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effectsTriggering Endogenous Cardiac Repair and Regeneration via Extracellular Vesicle-Mediated CommunicationTime for an "Atrial-Watchful" Approach for Heart Failure Patients With a Cardiac Implantable Electronic DeviceNo indication for right heart catheterisation for patients with isolated severe obstructive sleep apnoea syndrome according to a guideline-recommended approachModes of death and prognostic outliers in chronic heart failureIncreased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stressThe role of mitochondrial dynamics in cardiovascular diseasesIdentification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin WiselyIntravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicityCauses and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failureAntithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysisIndoxyl Sulfate Induces Renal Fibroblast Activation through a Targetable Heat Shock Protein 90-Dependent Pathway
P50
Q26741182-8CE81381-4FCF-4D64-A3BA-F616A8CA3DDBQ28087776-F603FD8F-F9DD-4175-B242-BC5AFA22ACF2Q30358722-2C3E0CF7-0C39-4627-893B-B8028149FBBEQ30363344-8B560C3A-D03D-4110-BEA5-06F6789641DDQ34368622-CE47C6A4-069C-48E7-A57D-6235507826BCQ34534895-6A129549-B1CF-4D10-8DF8-EB3D1CBE1BB8Q35000609-DE488888-2A6F-48AF-BEF5-CF11F0ECA3AEQ36274093-793449A9-C07F-43C7-A960-92CD8B1E25F4Q37443847-F490D6E7-F52D-42EC-9EA9-D9FE379FE24AQ38299496-FF2A22EE-8A40-4EB3-927F-0BB9CD7B592AQ38814570-DD6B7144-E855-41DA-8CDB-3EDF361135F6Q38819503-B0F297FE-BDBD-49EC-97C0-4995D11ED612Q39749031-CAD070D0-B0EE-40E1-A2FB-69BC6F77C49EQ40147440-7F1B15D5-056F-4F4D-A94E-A663AE7046E4Q40766741-4646EA5A-93C6-4E23-A3C6-FC98A791D306Q41102231-6DA4C25F-4CB0-4522-854E-8311BD5BADF1Q42214833-9299C651-A4B2-43DB-AD03-A89B0AC6BAA8Q47239900-10352D0B-E6A2-4C42-8919-6E890A2546CEQ47735687-5A5CDA58-F574-4AEB-9DDC-163A1655D70FQ48305554-F725E09F-177D-4A5D-BD4B-09F415FB840CQ48850461-31F7B4C7-A8A8-45DD-ABEF-28852354F040Q49379857-72644DD7-EB56-479B-B6BC-77B71A34DE87Q49953587-82E200C2-EB5C-449D-8B46-1FB565D5F966Q50089120-AA67B7A2-850D-4F02-AE96-3CD1F896040CQ51751360-29EE81B8-5F87-45D9-9361-9F12A44F50E3Q51760757-D7CC3327-9636-4299-AB45-7BFCE2725AFEQ57788044-481CF766-D8BA-4B99-B6B7-2576F42139B1Q57823940-9BCEC1B7-F138-47AC-AD95-A09D5D6E351DQ58197455-587BDE58-3EE6-458B-B62D-8A5BFFEB092CQ58573582-35A6CF76-BD51-43CA-ABDB-3F9ABB6B6E37Q88006150-9703D3EC-40AA-40DF-AEDE-2F2E6C14497EQ90462568-AD19E197-3DE2-4DC1-BD1B-2396E7D868E2Q90721932-4115832C-71B0-4902-8315-385E802B5D10Q91430804-4365CBF3-9BC8-4F07-9539-190F03830C80Q91956546-6B259672-269F-4E92-9AE6-9F5B0E1879AAQ91988875-955A4602-1996-422D-A6EF-47BDC908F072Q92098960-EE923159-CBAA-4A37-BE6E-5D401896A380Q92136476-8610F64E-C402-4D44-870D-979D5EDDB2C4Q92215710-5F83CD4A-B3CC-464F-A905-C13F1EC8D9D1Q92618428-93FBBF86-6C1E-4595-A688-55FFAE4D9C60
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Pietro Ameri
@en
Pietro Ameri
@nl
type
label
Pietro Ameri
@en
Pietro Ameri
@nl
prefLabel
Pietro Ameri
@en
Pietro Ameri
@nl
P31
P496
0000-0001-7167-7287